Hengrui Pharmaceutical (01276): SHR-3079 injection approved for clinical trials

Zhitongcaijing · 3d ago

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Suzhou Shengdia Biomedical Co., Ltd., a subsidiary of the company, has received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for SHR-3079 injections and will conduct clinical trials in the near future.

SHR-3079 injection is an innovative drug independently developed by the company. It is intended to be used to treat adult systemic lupus erythematosus and adult rheumatoid arthritis. At the same time, phase I clinical trials of this drug to treat B-cell non-Hodgkin lymphoma are underway. According to inquiries, there are currently no similar drugs approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-3079 injection-related projects is approximately RMB 24.4 million (unaudited).